{"id":65644,"date":"2026-05-19T19:05:32","date_gmt":"2026-05-19T11:05:32","guid":{"rendered":"https:\/\/flcube.com\/?p=65644"},"modified":"2026-05-19T19:05:33","modified_gmt":"2026-05-19T11:05:33","slug":"full-life-technologies-secures-150m-financing-to-advance-radiopharmaceutical-pipeline-and-establish-independent-actinium-225-production","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65644","title":{"rendered":"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production"},"content":{"rendered":"\n<p><strong>Full-Life Technologies<\/strong> announced the successful completion of a <strong>$150 million financing round<\/strong>, comprising <strong>$110 million in Series D equity<\/strong> and <strong>$40 million in debt financing<\/strong>. The round was <strong>led by Vivo Capital<\/strong> and included participation from strategic partner <strong>SK Biopharmaceuticals Co., Ltd.<\/strong>, alongside existing investors <strong>Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital<\/strong>, and other prominent shareholders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-structure-amp-investor-consortium\">Financing Structure &amp; Investor Consortium<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Lead\/Key Participants<\/th><\/tr><\/thead><tbody><tr><td><strong>Series D Equity<\/strong><\/td><td>$110M<\/td><td>Vivo Capital (lead), SK Biopharmaceuticals (strategic)<\/td><\/tr><tr><td><strong>Debt Financing<\/strong><\/td><td>$40M<\/td><td>Consortium of institutional lenders<\/td><\/tr><tr><td><strong>Total Raised<\/strong><\/td><td>$150M<\/td><td>Multi-tier investor syndicate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-pipeline-advancement\">Clinical Pipeline Advancement<\/h2>\n\n\n\n<p>The proceeds will primarily accelerate Full-Life&#8217;s <strong>clinical-stage radiopharmaceutical pipeline<\/strong>, with focus on two lead candidates:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>[\u00b2\u00b2\u2075Ac]Ac-FL-020<\/strong>: A potential <strong>best-in-class therapeutic<\/strong> for <strong>prostate cancer<\/strong>, leveraging the company&#8217;s proprietary targeting technology<\/li>\n\n\n\n<li><strong>[\u00b2\u00b2\u2075Ac]Ac-FL-261<\/strong>: A potential <strong>first-in-class drug<\/strong> for <strong>multiple solid tumor indications<\/strong>, representing novel mechanism of action in the radiopharmaceutical space<\/li>\n<\/ul>\n\n\n\n<p>By <strong>year-end 2026<\/strong>, Full-Life expects to have <strong>three differentiated clinical-stage programs<\/strong> advancing simultaneously, all originating from its proprietary <strong>UniRDC discovery platform<\/strong> that enables rapid identification and optimization of radiopharmaceutical candidates.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-manufacturing-initiative\">Strategic Manufacturing Initiative<\/h2>\n\n\n\n<p>A significant portion of the funding will support the <strong>initiation of GMP-grade \u00b2\u00b2\u2075Ac (Actinium-225) isotope production<\/strong> at the company&#8217;s <strong>advanced manufacturing facility in Belgium<\/strong>. This vertical integration strategy addresses critical industry constraints:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Supply Chain Security:<\/strong> Independent control over \u00b2\u00b2\u2075Ac production eliminates reliance on limited global suppliers<\/li>\n\n\n\n<li><strong>Quality Assurance:<\/strong> In-house GMP production ensures consistent isotope quality for clinical and commercial supply<\/li>\n\n\n\n<li><strong>Scalability:<\/strong> Dedicated production capacity enables rapid scale-up to meet anticipated clinical trial and commercial demand<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> Proprietary isotope production capability represents a significant strategic advantage in the capital-intensive radiopharmaceutical sector<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-industry-dynamics\">Market Context &amp; Industry Dynamics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Radiopharmaceutical Renaissance:<\/strong> The targeted alpha therapy market is projected to reach $8.5 billion by 2030, growing at 18% CAGR, driven by superior efficacy and safety profiles compared to traditional radiotherapies<\/li>\n\n\n\n<li><strong>Isotope Scarcity Challenge:<\/strong> Global \u00b2\u00b2\u2075Ac supply currently meets less than 30% of projected clinical demand, creating significant barriers to entry for new players<\/li>\n\n\n\n<li><strong>Asian Innovation Hub:<\/strong> Full-Life represents the vanguard of Chinese biotech companies expanding globally in specialized therapeutic areas, with European manufacturing ensuring regulatory compliance across major markets<\/li>\n\n\n\n<li><strong>Strategic Partnership Value:<\/strong> SK Biopharmaceuticals&#8217; participation signals strong validation of Full-Life&#8217;s technology platform and provides potential commercialization pathways in Asia-Pacific markets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, manufacturing capabilities, and market opportunities. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, manufacturing scale-up challenges, and competitive dynamics in the radiopharmaceutical sector.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65645,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,20,514],"class_list":["post-65644","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-finance","tag-full-life-technologies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million in Series D equity and $40 million in debt financing. The round was led by Vivo Capital and included participation from strategic partner SK Biopharmaceuticals Co., Ltd., alongside existing investors Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, and other prominent shareholders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65644\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production\" \/>\n<meta property=\"og:description\" content=\"Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million in Series D equity and $40 million in debt financing. The round was led by Vivo Capital and included participation from strategic partner SK Biopharmaceuticals Co., Ltd., alongside existing investors Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, and other prominent shareholders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65644\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T11:05:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T11:05:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production\",\"datePublished\":\"2026-05-19T11:05:32+00:00\",\"dateModified\":\"2026-05-19T11:05:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1901.webp\",\"keywords\":[\"Cancer\",\"Finance\",\"Full-Life Technologies\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65644#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65644\",\"name\":\"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1901.webp\",\"datePublished\":\"2026-05-19T11:05:32+00:00\",\"dateModified\":\"2026-05-19T11:05:33+00:00\",\"description\":\"Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million in Series D equity and $40 million in debt financing. The round was led by Vivo Capital and included participation from strategic partner SK Biopharmaceuticals Co., Ltd., alongside existing investors Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, and other prominent shareholders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65644\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65644#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production - Insight, China&#039;s Pharmaceutical Industry","description":"Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million in Series D equity and $40 million in debt financing. The round was led by Vivo Capital and included participation from strategic partner SK Biopharmaceuticals Co., Ltd., alongside existing investors Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, and other prominent shareholders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65644","og_locale":"en_US","og_type":"article","og_title":"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production","og_description":"Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million in Series D equity and $40 million in debt financing. The round was led by Vivo Capital and included participation from strategic partner SK Biopharmaceuticals Co., Ltd., alongside existing investors Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, and other prominent shareholders.","og_url":"https:\/\/flcube.com\/?p=65644","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T11:05:32+00:00","article_modified_time":"2026-05-19T11:05:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65644#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65644"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production","datePublished":"2026-05-19T11:05:32+00:00","dateModified":"2026-05-19T11:05:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65644"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65644#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1901.webp","keywords":["Cancer","Finance","Full-Life Technologies"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65644#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65644","url":"https:\/\/flcube.com\/?p=65644","name":"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65644#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65644#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1901.webp","datePublished":"2026-05-19T11:05:32+00:00","dateModified":"2026-05-19T11:05:33+00:00","description":"Full-Life Technologies announced the successful completion of a $150 million financing round, comprising $110 million in Series D equity and $40 million in debt financing. The round was led by Vivo Capital and included participation from strategic partner SK Biopharmaceuticals Co., Ltd., alongside existing investors Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, and other prominent shareholders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65644#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65644"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65644#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1901.webp","width":1080,"height":608,"caption":"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65644#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65644"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65644\/revisions"}],"predecessor-version":[{"id":65646,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65644\/revisions\/65646"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65645"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}